海辰药业(300584) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 116,400,513.71, representing a 4.27% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 2,947,505.95, an increase of 24.84% compared to the same period last year[5]. - The company's basic earnings per share for Q3 2023 was CNY 0.0246, up 24.87% from the same period last year[5]. - Net profit for the period increased to CNY 22,422,432.46, up 13.4% from CNY 19,757,915.43 in the same period last year[18]. - Earnings per share (EPS) rose to CNY 0.1869, compared to CNY 0.1674 in the previous period, marking an increase of 10.5%[19]. Cash Flow - The net cash flow from operating activities reached CNY 19,474,793.85, a significant increase of 136.33% year-over-year[9]. - The net cash flow from operating activities was ¥19,474,793.85, a decrease of ¥53,606,799.17 compared to the previous period[21]. - The net cash flow from investing activities was -¥80,158,313.77, down from ¥101,958,136.28 in the previous period[21]. - Cash inflow from financing activities totaled ¥176,000,000.00, compared to ¥269,000,000.00 in the previous period[21]. - The net cash flow from financing activities was ¥38,049,967.89, an improvement from -¥72,014,597.20 in the previous period[21]. - The ending balance of cash and cash equivalents was ¥72,442,103.38, down from ¥90,115,539.62 in the previous period[21]. - The cash inflow from loans received was ¥147,000,000.00, compared to ¥240,000,000.00 in the previous period[21]. - Cash outflow for debt repayment was ¥99,450,000.00, down from ¥274,000,000.00 in the previous period[21]. - The cash outflow for dividend distribution and interest payments was ¥4,656,873.22, compared to ¥34,314,597.20 in the previous period[21]. - The impact of exchange rate changes on cash and cash equivalents was ¥7,531.94, compared to -¥16,768.56 in the previous period[21]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 1,341,192,183.09, reflecting a 3.65% increase from the end of the previous year[5]. - Current assets total CNY 367,244,999.44, a decrease from CNY 378,378,861.18 at the start of the year[14]. - Inventory has increased to CNY 78,313,347.14 from CNY 64,131,809.31 at the beginning of the year, reflecting a growth of approximately 22.1%[14]. - The company's cash and cash equivalents decreased to CNY 72,442,103.38 from CNY 95,068,123.47, a decline of about 23.8%[13]. - Non-current assets total CNY 973,947,183.65, up from CNY 915,566,549.11 at the beginning of the year[14]. - The total liabilities amount to CNY 344,737,918.45, an increase from CNY 317,045,536.08 at the start of the year[14]. - The total liabilities increased to CNY 367,557,459.00 from CNY 343,379,013.86, reflecting a rise of 7.0%[18]. - Total equity attributable to shareholders rose to CNY 973,634,724.09, up from CNY 950,566,396.43, an increase of 2.5%[18]. Expenses - Research and development expenses surged to CNY 31,900,346.61, marking a 121.45% increase due to the initiation of multiple new projects[8]. - Research and development expenses increased significantly to CNY 31,900,346.61, up from CNY 14,405,381.84, indicating a focus on innovation[17]. - The company experienced a 34.49% increase in non-operating expenses, primarily due to donations and fixed asset write-offs[9]. - Sales expenses decreased to CNY 180,025,425.29 from CNY 186,390,916.67, showing improved cost management[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,428[10]. - The largest shareholder, Cao Yuping, holds 42.08% of the shares, amounting to 50,491,306 shares, with 3,200,000 shares pledged[10]. Audit and Reporting - The company did not undergo an audit for the third quarter report[22].